Zhejiang Chinagene Biopharmaceutical

Zhejiang Chinagene Biopharmaceutical is a high-tech biotechnology company based in Zhejiang, China, specializing in the development of recombinant protein therapeutics using its proprietary silkworm baculovirus expression vector system (BEVS). The company's platform utilizes silkworm pupae as bioreactors to produce complex eukaryotic proteins, enabling oral delivery of biologics by protecting them from gastrointestinal degradation. Its lead clinical candidate is BmrhGM-CSF (an oral molgramostim biosimilar) for the treatment of chemotherapy-induced leukopenia, which has entered Phase 1 clinical trials. Additionally, Zhejiang Chinagene is advancing preclinical programs such as CTB-APSL for type 2 diabetes and BmrhGH for growth hormone deficiency, alongside a portfolio of approved health products and cosmetics.